Preventing the Recurrence
of Melanoma

About Polynoma

An immuno-oncology company developing a novel vaccine for the adjuvant treatment of melanoma.

The Technology

Polyvalent shed antigens stimulate both humoral and cellular immune responses.

Clinical Trials

MAVIS (Melanoma Antigen Vaccine Immunotherapy Study) is a multicenter, double-blind, placebo-controlled adaptive Phase III trial to assess the safety and efficacy of seviprotimut-L.